Generics Bulletin’s Top 50 Ranking For 2022
Compiling All The Data From Our List Of The Top Industry Players
Executive Summary
This article compiles all the data from Generics Bulletin’s 2022 ranking of the top 50 generics and biosimilars companies, including additional details of how the financial figures stack up.
You may also be interested in...
$60m For Mexico’s Genomma From World Bank Group’s Private Sector Arm
IFC, the private sector arm of the World Bank Group, has loaned $60m to Mexican Pharmaceutical Genomma, building on its long track record in Latin American health investments.
Celltrion To Jostle For Space In Crowded EU Bevacizumab Market
The European Commission has approved Vegzelma, a bevacizumab biosimilar developed by South Korean biopharma giant Celltrion. Vegzelma joins nine other bevacizumab biosimilar marketing authorization applications approved in the EU, promising to intensify price competition for the critical late-stage cancer treatment.
Sandoz Maintains Lead On Denosumab As It Files With FDA
Sandoz has confirmed that its denosumab biosimilar BLA has been accepted for review by the US FDA. The company – which has previously characterized its development program as a frontrunner compared to other proposed Prolia/Xgeva rivals – indicated that it was “among the first” to file.